Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	53.17M 38.13M 32.9M 30.99M 28.24M 52.78M 3.6B 367M 142M 1.84B 143M 140M 6.05B	P/E 2026 *	-2x	P/E 2027 *	-2.15x
Enterprise Value	53.17M 38.13M 32.9M 30.99M 28.24M 52.78M 3.6B 367M 142M 1.84B 143M 140M 6.05B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	87.66%	Yield 2026 *	-	Yield 2027 *	-

08-25	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
08-11	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI
07-23	Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT
05-15	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI
05-15	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-14	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea	RE
05-14	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea	CI
04-22	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints	CI
03-27	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position	RE
03-25	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation	CI
03-17	Incannex regains compliance with Nasdaq minimum bid price requirement	RE

08-25	Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X	AQ
08-11	Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026	AQ
07-23	Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea	AQ
06-25	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ
06-10	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility	AQ

Manager	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	37	01/01/2016
Joseph Swan DFI	Director of Finance/CFO	35	29/02/2024
Luigi Barbato CTO	Chief Tech/Sci/R&D Officer	63	21/10/2024

Director	Title	Age	Since
Troy Valentine CHM	Chairman	52	01/11/2023
Peter Widdows BRD	Director/Board Member	60	01/11/2023
Joel Latham BRD	Director/Board Member	37	01/01/2016

Incannex Healthcare Stock Australian S.E.

Stocks

IHL

AU000000IHL8

Biotechnology & Medical Research

Valuation : Incannex Healthcare

Latest news : Incannex Healthcare

Analysts' recommendations : Incannex Healthcare

Press Releases : Incannex Healthcare

Quotes and Performance

Managers and Directors : Incannex Healthcare

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INCANNEX HEALTHCARE	-10.87%	-31.67%	-	-	38.05M
WUXI APPTEC CO., LTD.	+1.03%	-3.11%	+39.80%	+94.60%	68.21B
ARGENX SE	+1.62%	+0.33%	+48.61%	+89.64%	64.25B
INSMED INCORPORATED	+1.51%	-0.93%	-15.19%	+367.31%	26.54B
BIONTECH SE	+1.16%	-8.26%	+2.63%	-15.36%	25.61B
GENMAB A/S	+1.30%	+0.74%	+31.66%	-18.33%	19.88B
PHARMAESSENTIA CORPORATION	-0.38%	-12.42%	+224.86%	+373.18%	17.13B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.65%	-5.83%	+1.44%	+544.44%	14.93B
EXELIXIS, INC.	+1.56%	+2.83%	+55.15%	+159.03%	14.1B
MADRIGAL PHARMACEUTICALS, INC.	+0.91%	+0.52%	+24.20%	+193.59%	12.45B
Average	-0.15%	-3.75%	+45.91%	+198.68%	29.23B
Weighted average by Cap.	+1.17%	-3.01%	+42.13%	+153.46%

	2026 *	2027 *
Net sales	-	-
Net income	-24.91M -17.87M -15.41M -14.52M -13.23M -24.73M -1.69B -172M -66.72M -863M -67.09M -65.63M -2.83B	-24.89M -17.85M -15.4M -14.5M -13.21M -24.7M -1.69B -172M -66.64M -862M -67.02M -65.55M -2.83B
Net Debt	-	-